Table 1.

Laboratory test values on admission and after treatment initiation.

Lab value (Reference range)	Patient 1		Patient 2
	Initially	∼4 weeks into eculizumab treatment	Initially	∼4 weeks into eculizumab treatment
Hemoglobin (11.5−15.8 g/dL)	8.9	10.2	9.5	12.1
Platelet count (140–400 K/µL)	104	382	19	243
Reticulocytic count (2000−110,000 /µL)	72,800	–	59,900	–
Reticulocytic percentage (0.5−2.3%)	2.9%	–	1.5%	–
D-dimer (< = 0.50 µg/mL)	4.23	–	> 20.00	2.91
Fibrinogen	357	–	458
International normalized ratio (INR) (0.85–1.12)	1.07	–	1.13	1.05
Activated partial thromboplastin time (aPTT) (23.5–36.5 s)	31.1	–	41.6	23.6
Serum creatinine (0.50−1.30 mg/dL)	8.87	1.53	3.14	1.33
eGFR (>90 mL/min/1.73 m2)	5	50	23	64
Total bilirubin (0.0−1.3 mg/dL)	0.9	<0.1	5.5	0.9
LDH (105–229 U/L)	1272	135	1956	175
Haptoglobin (32−197 mg/dL)	<6	–	14	–
Ferritin (12–275 ng/mL)	1001	–	>40,000	–
Serum complement, alternate path (> = 46 % of norm)	–	–	86%	–